Oyster Point Pharma - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsOyster Point Pharma

Oyster Point Pharma(OYST)

Oyster Point Pharma, Inc. is an American biopharmaceutical based in Princeton, New Jersey, focusing on the development of pharmaceutical therapies to treat ophthalmic diseases.

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Tyrvaya	Varenicline	2021-10-15	2035	Tobacco use cessation

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

head and neck neoplasms

,

healthy volunteers/patients

,

,

squamous cell carcinoma of head and neck

,

squamous cell carcinoma

,

pharmacokinetics

,

,

nasopharyngeal carcinoma

,

nasopharyngeal neoplasms

,

biological availability

,

amphetamine-related disorders

,

cocaine-related disorders

,

,

second primary neoplasms

,

,

spinocerebellar degenerations

,

spinocerebellar ataxias

,

machado-joseph disease

,

post-traumatic stress disorders

,

traumatic stress disorders

,

alzheimer disease

,

sleep initiation and maintenance disorders

,

,

,

smoking reduction

,

,

,

cerebellar ataxia

,

,

disease progression

,

,

friedreich ataxia

,

smoking cessation

,

tobacco use disorder

,

,

cigarette smoking

,

,

,

dry eye syndromes

,

tobacco use cessation

,

alcohol drinking

,

keratoconjunctivitis sicca

,

,

,

tobacco smoking

,

substance-related disorders

,

,

,

psychotic disorders

,

cardiovascular diseases

,

,

mental disorders

,

acquired immunodeficiency syndrome

,

chronic obstructive pulmonary disease

,

,

parkinson disease

,

,

obstructive lung diseases

,

bipolar disorder

,

,

depressive disorder

,

medication adherence

,

acute coronary syndrome

,

,

addictive behavior

,

opioid-related disorders

,

coronary disease

,

coronary artery disease

,

myocardial ischemia

,

marijuana abuse

,

problem behavior

,

,

,

alcoholic intoxication

,

cognitive dysfunction

,

,

immunologic deficiency syndromes

,

,

keratoconjunctivitis

,

,

,

sleep wake disorders

,

,

,

substance withdrawal syndrome

,

parkinsonian disorders

,

tardive dyskinesia

,

,

genetic predisposition to disease

,

,

disorders of excessive somnolence

,

,

major depressive disorder

,

,

hypersensitivity

,

cerebrovascular disorders

,

,

attention deficit disorder with hyperactivity

,

,

cognition disorders

,

sjogren's syndrome

,

,

,

diabetes mellitus

,

,

non-small-cell lung carcinoma

,

thoracic surgical procedures

,

health behavior

,

myocardial infarction

,

respiratory tract diseases

,

respiration disorders

,

,

,

prediabetic state

,

glucose intolerance

,

,

breast neoplasms

,

,

congenital abnormalities

,

,

communicable diseases

,

,

pancreatic neoplasms

,

stomach neoplasms

,

esophageal neoplasms

,

urinary bladder neoplasms

,

liver neoplasms

,

kidney neoplasms

,

uterine cervical neoplasms

,

rheumatoid arthritis

,

,

urologic neoplasms

,

intraoperative complications

,

postoperative complications

,

female genital neoplasms

,

thoracic neoplasms

,

abdominal neoplasms

,

atopic dermatitis

,

,

,

keratoconjunctivitis sicca

,

dry eye syndromes

,

© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use